Considering that TOPIIα is a molecular target for drugs from the anthracycline group, it can be concluded that the differences in protein expression observed in our study in different individuals with DLBCL causes different responses to treatment with TOPIIα inhibitors. Here, TOP2A is linked to diffuse large B-cell lymphoma.